Access

Letter

Nature Medicine 14, 1351–1356 (1 December 2008) | doi:10.1038/nm.1890

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Jeffrey A Engelman , Liang Chen , Xiaohong Tan , Katherine Crosby , Alexander R Guimaraes , Rabi Upadhyay , Michel Maira , Kate McNamara , Samanthi A Perera , Youngchul Song , Lucian R Chirieac , Ramneet Kaur , Angela Lightbown , Jessica Simendinger , Timothy Li , Robert F Padera , Carlos Garc|[iacute]|a-Echeverr|[iacute]|a , Ralph Weissleder , Umar Mahmood , Lewis C Cantley & Kwok-Kin Wong

Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the p110-α catalytic subunit (encoded by PIK3CA). They are most frequently observed in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R).